A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study aims to assess the efficacy and safety of neoadjuvant adjuvant treatment with durvalumab in combination with FLOT compared to placebo in combination with FLOT in Chinese patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN-CN).
Epistemonikos ID: 9f6994f14fe71158e8192caaf3f62a66376ba695
First added on: Oct 17, 2026